|
||||||
Executive Summary House Dust Mite Allergy-Pipeline Review, H1 2015 Summary Global Markets Direct's, 'House Dust Mite Allergy-Pipeline Review, H1 2015', provides an overview of the House Dust Mite Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons To Buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Read More Contact Us:
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 House Dust Mite Allergy Overview 6 Therapeutics Development 7 Pipeline Products for House Dust Mite Allergy-Overview 7 Pipeline Products for House Dust Mite Allergy-Comparative Analysis 8 House Dust Mite Allergy-Therapeutics under Development by Companies 9 House Dust Mite Allergy-Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 House Dust Mite Allergy-Products under Development by Companies 13 House Dust Mite Allergy-Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Anergis SA 15 Biomay AG 16 Circassia Pharmaceuticals plc 17 DBV Technologies S.A. 18 HAL Allergy BV 19 Stallergenes S.A. 20 House Dust Mite Allergy-Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AllerDM-Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 allergenic pollen extract of timothy-Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 BM-35-Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 House Dust Mite-SPIRE-Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 MK-8237-Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PL-103-Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 S-524101-Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Viaskin House Dust Mite-Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 House Dust Mite Allergy-Recent Pipeline Updates 39 House Dust Mite Allergy-Dormant Projects 43 House Dust Mite Allergy-Discontinued Products 44 House Dust Mite Allergy-Product Development Milestones 45 Featured News & Press Releases 45 Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 45 Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 45 Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 46 Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 47 Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction 48 Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 49 Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 50 Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 51 Nov 14, 2012: DBV Technologies Launches Third Viaskin Program For Treatment Of House Dust Mites Allergy In Young Children 51 Oct 10, 2012: Merck Plans To Initiate Phase III Clinical Trial With HDM AIT In North America 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54 List of Tables Number of Products under Development for House Dust Mite Allergy, H1 2015 7 Number of Products under Development for House Dust Mite Allergy-Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 House Dust Mite Allergy-Pipeline by ALK-Abello A/S, H1 2015 14 House Dust Mite Allergy-Pipeline by Anergis SA, H1 2015 15 House Dust Mite Allergy-Pipeline by Biomay AG, H1 2015 16 House Dust Mite Allergy-Pipeline by Circassia Pharmaceuticals plc, H1 2015 17 House Dust Mite Allergy-Pipeline by DBV Technologies S.A., H1 2015 18 House Dust Mite Allergy-Pipeline by HAL Allergy BV, H1 2015 19 House Dust Mite Allergy-Pipeline by Stallergenes S.A., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 House Dust Mite Allergy Therapeutics-Recent Pipeline Updates, H1 2015 39 House Dust Mite Allergy-Dormant Projects, H1 2015 43 House Dust Mite Allergy-Discontinued Products, H1 2015 44 List of Figures Number of Products under Development for House Dust Mite Allergy, H1 2015 7 Number of Products under Development for House Dust Mite Allergy-Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Early Stage Products, H1 2015 12 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Top 10 Routes of Administration, H1 2015 23 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23 Number of Products by Top 10 Molecule Types, H1 2015 25 Number of Products by Stage and Top 10 Molecule Types, H1 2015 26 Single User License: Site License: Corporate User License: ALK-Abello A/S Anergis SA Biomay AG Circassia Pharmaceuticals plc DBV Technologies S.A. HAL Allergy BV Stallergenes S.A. House Dust Mite Allergy Therapeutic Products under Development, Key Players in House Dust Mite Allergy Therapeutics, House Dust Mite Allergy Pipeline Overview, House Dust Mite Allergy Pipeline, House Dust Mite Allergy Pipeline Assessment |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center" |